Medium-chain triglycerides increase energy expenditure and decrease adiposity in overweight men
Marie-Pierre St-Onge, Robert Ross, William D Parsons, Peter J H Jones, Marie-Pierre St-Onge, Robert Ross, William D Parsons, Peter J H Jones
Abstract
Objective: The objectives of this study were to compare the effects of diets rich in medium-chain triglycerides (MCTs) or long-chain triglycerides (LCTs) on body composition, energy expenditure, substrate oxidation, subjective appetite, and ad libitum energy intake in overweight men.
Research methods and procedures: Twenty-four healthy, overweight men with body mass indexes between 25 and 31 kg/m(2) consumed diets rich in MCT or LCT for 28 days each in a crossover randomized controlled trial. At baseline and after 4 weeks of each dietary intervention, energy expenditure was measured using indirect calorimetry, and body composition was analyzed using magnetic resonance imaging.
Results: Upper body adipose tissue (AT) decreased to a greater extent (p < 0.05) with functional oil (FctO) compared with olive oil (OL) consumption (-0.67 +/- 0.26 kg and -0.02 +/- 0.19 kg, respectively). There was a trend toward greater loss of whole-body subcutaneous AT volume (p = 0.087) with FctO compared with OL consumption. Average energy expenditure was 0.04 +/- 0.02 kcal/min greater (p < 0.05) on day 2 and 0.03 +/- 0.02 kcal/min (not significant) on day 28 with FctO compared with OL consumption. Similarly, average fat oxidation was greater (p = 0.052) with FctO compared with OL intake on day 2 but not day 28.
Discussion: Consumption of a diet rich in MCTs results in greater loss of AT compared with LCTs, perhaps due to increased energy expenditure and fat oxidation observed with MCT intake. Thus, MCTs may be considered as agents that aid in the prevention of obesity or potentially stimulate weight loss.
Source: PubMed
Bevorstehende klinische Studien
-
NCT07646600Noch keine Rekrutierung
-
NCT07646613Rekrutierung
-
NCT07646626RekrutierungLokal fortgeschrittene (nicht resezierbare) oder metastasierte solide Tumoren
-
NCT07646639RekrutierungDarmkrebs | Strahlentherapie
-
NCT07646652Noch keine Rekrutierung
-
NCT07646678Noch keine RekrutierungIdiopathische Hypersomnie | Narkolepsie Typ 1 | Narkolepsie Typ 2
-
NCT07646691Noch keine RekrutierungChronische Lungenerkrankungen
-
NCT07646704RekrutierungPersistierender Ductus arteriosus
-
NCT07646730RekrutierungPostoperative Komplikationen | Brustchirurgie | Perioperative Monitoring
-
NCT07646782RekrutierungHerz-Kreislauf-Erkrankungen | Neubildungen | Sterblichkeit | Berufsbedingte Krankheit | Kognitive Dysfunktion | Metabolisches Syndrom | Demenz | Gebrechlichkeit | Altern | Muskel-Skelett-Erkrankung
-
NCT07646808Noch keine Rekrutierung
-
NCT07646821Noch keine RekrutierungAzacitidin | MDS/AML | Ropeginterferon | Alfa-2b